Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer
…, M Saleh, P Richards, JM Specht… - Journal of clinical …, 2014 - ascopubs.org
Purpose There is a lack of treatments providing survival benefit for patients with metastatic
triple-negative breast cancer (mTNBC), with no standard of care. A randomized phase II trial …
triple-negative breast cancer (mTNBC), with no standard of care. A randomized phase II trial …
[PDF][PDF] Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade
…, C Berger, KS Smythe, SM Garrison, JM Specht… - Cancer cell, 2021 - cell.com
Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective
in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast …
in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast …
[HTML][HTML] Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally …
…, RB Livingston, HM Linden, JM Specht… - Journal of Clinical …, 2008 - ncbi.nlm.nih.gov
Purpose Patients with locally advanced breast carcinoma (LABC) receive preoperative
chemotherapy to provide early systemic treatment and assess in vivo tumor response. Serial …
chemotherapy to provide early systemic treatment and assess in vivo tumor response. Serial …
Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
JM Specht, G Wang, MT Do, JS Lam… - The Journal of …, 1997 - rupress.org
Dendritic cells (DCs) are bone marrow–derived leukocytes that function as potent antigen
presenting cells capable of initiating T cell–dependent responses from quiescent lymphocytes. …
presenting cells capable of initiating T cell–dependent responses from quiescent lymphocytes. …
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic …
…, LM Peterson, EK Schubert, JR Gralow, JM Specht… - Clinical Cancer …, 2011 - AACR
Purpose: To determine, by molecular imaging, how in vivo pharmacodynamics of estrogen-estrogen
receptor (ER) binding differ between types of standard endocrine therapy. …
receptor (ER) binding differ between types of standard endocrine therapy. …
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of …
LK Dunnwald, RK Doot, JM Specht, JR Gralow… - Clinical Cancer …, 2011 - AACR
Purpose: Changes in tumor metabolism from positron emission tomography (PET) in locally
advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NC) are …
advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NC) are …
A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
Purpose 16α-[ 18 F]-fluoro-17β-estradiol positron emission tomography (FES-PET)
quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit. …
quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit. …
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast …
…, X Chai, S Shepherd, V Giranda, JM Specht - Clinical Cancer …, 2016 - AACR
Purpose: Cisplatin is synergistic with vinorelbine and the PARP inhibitor veliparib, and has
antineoplastic activity in triple-negative breast cancer (TNBC) and BRCA mutation–…
antineoplastic activity in triple-negative breast cancer (TNBC) and BRCA mutation–…
A phase II study of 3′-deoxy-3′-18F-fluorothymidine PET in the assessment of early response of breast cancer to neoadjuvant chemotherapy: results from ACRIN …
…, JP Muzi, DA Pryma, JM Specht… - Journal of Nuclear …, 2015 - Soc Nuclear Med
Our objective was to determine whether early change in standardized uptake values (SUVs)
of 3′deoxy-3′- 18 F-fluorothymidine ( 18 F-FLT) using PET with CT could predict …
of 3′deoxy-3′- 18 F-fluorothymidine ( 18 F-FLT) using PET with CT could predict …
Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to …
JM Specht, SL Tam, BF Kurland, JR Gralow… - Breast cancer research …, 2007 - Springer
Background The response of bone-dominant (BD) breast cancer to therapy is difficult to assess
by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[ …
by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[ …